Tambocor

Indicated for cardiac arrhythmias, formulated to target sodium channels and alleviate electrical instability to support a normal heart rhythm.

Strengths: 50 · 100mg

Medicine details

Therapeutic class

Antiarrhythmic

Pharmacological class

Class Ic Antiarrhythmic

Contraindications

heart failure; history of myocardial infarction; second or third degree AV block

Precautions and warnings

regular ECG monitoring required; avoid in patients with structural heart disease

Minor side effects

dizziness; visual disturbances

Moderate side effects

arrhythmia pro-arrhythmic effect; shortness of breath; fatigue

Serious side effects

ventricular tachycardia — requires immediate medical attention

Dosage forms

Tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

3M

Onset Time

1–3 hours

Duration

12 hours

Storage instructions

Store below 25°C in a dry place.

Drug interactions

beta blockers; digoxin; amiodarone

Age restrictions

Dose adjusted based on weight in children.

Patient summary

Indicated for cardiac arrhythmias, formulated to target sodium channels and alleviate electrical instability to support a normal heart rhythm.

Mechanism of action

Flecainide is a Class Ic antiarrhythmic agent. It slows conduction in the cardiac tissues by blocking sodium channels, which helps reduce electrical excitability and restore regular rhythm in atrial and ventricular conduction systems.

Pregnancy and breastfeeding

Pregnancy: Use only if clearly necessary. Breastfeeding: Passes into milk, use with caution.

Tambocor

Indicated for cardiac arrhythmias, formulated to target sodium channels and alleviate electrical instability to support a normal heart rhythm.

Editorial Notes

  • Active ingredient(s): Flecainide
  • Listed indication(s): Atrial Fibrillation, Atrial Flutter, Ventricular Arrhythmias

Usually available as

  • 90 tablets - 50 mg1536-50-mg-18159
  • 60 tablets - 100 mg1536-100-mg-18165